Unique ID issued by UMIN | UMIN000041914 |
---|---|
Receipt number | R000044358 |
Scientific Title | Identification of biomarkers that predict responsiveness to Benralizumab among severe asthma |
Date of disclosure of the study information | 2020/09/28 |
Last modified on | 2022/06/01 16:19:31 |
Identification of biomarkers that predict responsiveness to Benralizumab among severe asthma
Biomarker for Benralizumab
Identification of biomarkers that predict responsiveness to Benralizumab among severe asthma
Biomarker for Benralizumab
Japan |
Asthma
Medicine in general | Clinical immunology |
Others
NO
Identification of biomarkers that predict responsiveness to Benralizumab
Others
Clarify effectiveness of Benralizumab among severe asthma.
Relationships between a change in GETE and serum cytokine levels
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1. Patient with severe asthma
2. Patient going to use Benralizumab
3. Patient using high dose ICS and other control agents
Patient whom the researchers think is not suitable for the study.
15
1st name | Maho |
Middle name | |
Last name | Suzukawa |
National Hospital Organization Tokyo National Hospital
Clinical Research Center
204-8585
3-1-1 Takeoka, Kiyose-Shi, Tokyo, Japan
042-491-2111
fueta-tky@umin.ac.jp
1st name | Maho |
Middle name | |
Last name | Suzukawa |
National Hospital Organization Tokyo National Hospital
Clinical Research Center
204-8585
3-1-1 Takeoka, Kiyose-Shi, Tokyo, Japan
042-491-2111
fueta-tky@umin.ac.jp
National Hospital Organization Tokyo National Hospital
National Hospital Organization Tokyo National Hospital
Self funding
Institutional Ethics Review Board of National Hospital Organization Tokyo National Hospital
3-1-1 Takeoka, Kiyose-Shi, Tokyo, Japan
042-491-2111
goto-yumiko@tokyo-hosp.jp
NO
2020 | Year | 09 | Month | 28 | Day |
https://www.tandfonline.com/doi/abs/10.1080/02770903.2021.1942039?journalCode=ijas20
Unpublished
https://www.tandfonline.com/doi/abs/10.1080/02770903.2021.1942039?journalCode=ijas20
20
There were nine respondents and eight non-respondents. The non-responders showed significantly higher baseline serum interferon-g; interleukin (IL)-4, -5, -6, -7, and -12p70; IL-17/IL-17A; IL-17E/IL-25; IL-18/IL-1F4; chemokine (C-C motif) ligand (CCL)3/macrophage inflammatory protein (MIP)-1a; CCL4/MIP-1b; CCL11/eotaxin; matrix metalloproteinase-12; tumor necrosis factor-a, and thymic stromal lymphopoietin levels.
2022 | Year | 06 | Month | 01 | Day |
Seventeen benralizumab-treated patients with severe eosinophilic asthma were enrolled.
Blood samples were collected; pulmonary function tests were performed and questionnaires were disseminated at baseline and after 1, 2, 4, and 6 months of treatment. Blood cytokine levels were measured. Response was defined as an elevation in forced expiratory volume in 1 s of at least 10.4% from baseline after 4 months of treatment.
N.A.
Cytokine levels of responders at baseline.
Completed
2018 | Year | 03 | Month | 01 | Day |
2018 | Year | 05 | Month | 30 | Day |
2018 | Year | 05 | Month | 30 | Day |
2020 | Year | 08 | Month | 30 | Day |
This study will end at March, 31, 2021.
2020 | Year | 09 | Month | 28 | Day |
2022 | Year | 06 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044358
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |